» Articles » PMID: 37801170

Colorectal Cancer Cell Membrane Biomimetic Ferroferric Oxide Nanomaterials for Homologous Bio-imaging and Chemotherapy Application

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2023 Oct 6
PMID 37801170
Authors
Affiliations
Soon will be listed here.
Abstract

The research of nanomaterials for bio-imaging and theranostic are very active nowadays with unprecedented advantages in nanomedicine. Homologous targeting and bio-imaging greatly improve the ability of targeted drug delivery and enhance active targeting and treatment ability of nanomedicine for the tumor. In this work, lycorine hydrochloride (LH) and magnetic iron oxide nanoparticles coated with a colorectal cancer (CRC) cell membrane (LH-FeO@M) were prepared, for homologous targeting, magnetic resonance imaging (MRI), and chemotherapy. Results showed that the LH-FeO@M and FeO@M intensity at HT29 tumor was significantly higher than that FeO@PEG, proving the superior selectivity of cancer cell membrane-camouflaged nanomedicine for homologous tumors and the MRI effect of darkening contrast enhancement were remarkable at HT29 tumor. The LH-FeO@M exhibited excellent chemotherapy effect in CRC models as well as LH alone and achieved a high tumor ablation rate but no damage to normal tissues and cells. Therefore, our biomimetic system achieved a homologous targeting, bio-imaging, and efficient therapeutic effect of CRC.

Citing Articles

Homologous-adhering/targeting cell membrane- and cell-mediated delivery systems: a cancer-catch-cancer strategy in cancer therapy.

Liu C, Gao J, Cheng Y, Zhang S, Fu C Regen Biomater. 2025; 12:rbae135.

PMID: 39811105 PMC: 11729729. DOI: 10.1093/rb/rbae135.


Cancer cell membrane-coated nanoparticles: a promising anti-tumor bionic platform.

Guo Q, Wang S, Xu R, Tang Y, Xia X RSC Adv. 2024; 14(15):10608-10637.

PMID: 38567339 PMC: 10985588. DOI: 10.1039/d4ra01026d.

References
1.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

2.
Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F . Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer. 2018; 144(12):2992-3000. DOI: 10.1002/ijc.32055. View

3.
Schreuders E, Ruco A, Rabeneck L, Schoen R, Sung J, Young G . Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64(10):1637-49. DOI: 10.1136/gutjnl-2014-309086. View

4.
Edwards B, Ward E, Kohler B, Eheman C, Zauber A, Anderson R . Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2009; 116(3):544-73. PMC: 3619726. DOI: 10.1002/cncr.24760. View

5.
Bondeven P, Hagemann-Madsen R, Laurberg S, Ginnerup Pedersen B . Extent and completeness of mesorectal excision evaluated by postoperative magnetic resonance imaging. Br J Surg. 2013; 100(10):1357-67. DOI: 10.1002/bjs.9225. View